Evidence map›Paper›PMID 39907981›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025

Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

Milene Vitória Sampaio Sobral, Livia Kneipp Rodrigues, Abner Mácola Pacheco Barbosa, Naila Camila da Rocha, Isac Ribeiro Moulaz, João Pedro Pereira Dos Santos, Bruno Henrique Couto Oliveira, João Lucas de Magalhães Leal Moreira, Francis Lopes Pacagnelli, Camila Mota Guida

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Milene Vitória Sampaio Sobral *University of Western Sao Paulo, Presidente Prudente, Brazil.ORCID http://orcid.org/0009-0001-5754-6472
Livia Kneipp Rodrigues *Federal University of Minas Gerais, Belo Horizonte, Brazil.
Abner Mácola Pacheco BarbosaSão Paulo State University, Botucatu, Brazil.
Naila Camila da RochaSão Paulo State University, Botucatu, Brazil.
Isac Ribeiro MoulazFederal University of Espirito Santo, Vitoria, Brazil.
João Pedro Pereira Dos SantosUniversity of Western Sao Paulo, Presidente Prudente, Brazil.
Bruno Henrique Couto OliveiraUniversity of Western Sao Paulo, Presidente Prudente, Brazil.
João Lucas de Magalhães Leal MoreiraState University of Feira de Santana, Feira de Santana, Brazil.
Francis Lopes PacagnelliUniversity of Western Sao Paulo, Presidente Prudente, Brazil.
Camila Mota GuidaDante Pazzanese Institute of Cardiology, Av. Dante Pazzanese, Sao Paulo, 500, Brazil. camila.mguida@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSemaglutide has emerged as an effective medication for treating type 2 diabetes mellitus (DM). However, the cardiovascular effects and safety of this agent in patients with heart failure with preserved ejection fraction (HFpEF) are unclear.

objectiveThis systematic review and meta-analysis aimed to assess the clinical and laboratory effects of semaglutide compared to placebo in patients with HFpEF.

methodsWe systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials (RCTs) and non-randomized cohorts, from inception to July 2024, comparing semaglutide versus placebo in patients with HFpEF. Statistical analyses were performed using R Studio 4.3.2. Mean difference (MD) and odds ratio (OR) with 95% confidence intervals (CIs) were pooled across trials.

resultsThis meta-analysis included three studies, two RCTs and one non-randomized cohort, reporting data on 1463 patients. The follow-up time of the studies was 52 weeks. Compared to placebo, the use of semaglutide was associated with a significant increase in the 6-min walk distance (MD 16.20; 95% CI 10.19-22.21; p < 0.01; I

conclusionThese findings suggest that the use of semaglutide is associated with clinical and laboratory benefits in patients with HFpEF.

Indexed as

Glucagon-Like PeptidesHeart FailureStroke VolumeDiabetes Mellitus, Type 2Glucagon-Like Peptide 1HumansNatriuretic Peptide, BrainRandomized Controlled Trials as TopicSemaglutideGlucagon-Like Peptide 1Glucagon-Like PeptidesNatriuretic Peptide, BrainSemaglutide

Identifiers

PMID39907981

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.